1
|
Dimitrakopoulos FI, Christopoulos P, Elshiaty M, Daniello L, Pyrousis I, Kottorou A, Makatsoris T, Kalofonos H, Koutras A. EP08.01-072 Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
2
|
Kottorou A, Dimitrakopoulos F, Antonacopoulou A, Makatsoris T, Stavropoulos M, Koutras A, Kalofonos H. P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Grivas P, Park S, Voog E, Caserta C, Perez Valderrama B, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A, Loriot Y, Sridhar S, Tsuchiya N, Kopyltsov E, Gupta S, Huang B, Costa N, Blake-Haskins J, di Pietro A, Powles T. 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.776] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Papachristos A, Karatza E, Kalofonos H, Sivolapenko G. 127P Personalizing treatment in colorectal cancer by monitoring bevacizumab blood levels and ICAM-1 polymorphisms. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
5
|
Dimitrakopoulos FI, Antonacopoulou A, Kottorou A, Tzelepi V, Panagopoulos N, Kalofonou M, Dougenis D, Koutras A, Makatsoris T, Kalofonos H. Genetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz073.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Sirinian C, Papanastasiou A, Schizas M, Spella M, Stathopoulos G, Kalofonos H. Isoform RANK-c affects stem cell properties of breast cancer cells. Breast 2019. [DOI: 10.1016/s0960-9776(19)30151-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
Tsoukalas N, Papakotoulas P, Christopoulou A, Ardavanis A, Koumakis G, Papandreou C, Papatsimpas G, Papakostas P, Andreadis C, Aravantinos G, Ziras N, Kalofonos H, Samantas E, Sougleri M, Makrantonakis P, Pentheroudakis G, Athanasiadis A, Bournakis E, Varthalitis I, Boukovinas I. Prevention and prophylaxis of thrombosis in cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Dimitrakopoulos FI, Antonacopoulou A, Kottorou A, Marousi S, Koukourikou I, Scopa C, Dougenis D, Tzelepi V, Kalofonos H. Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Procopio G, Bamias A, Schmidinger M, Hawkins R, Rodriguez Sanchez A, Vazquez S, Srihari N, Kalofonos H, Bono P, Pisal C, Hirschberg Y, Dezzani L, Ahmad Q, Suarez Rodriguez C, Jonasch E. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Antonacopoulou A, Kottorou A, Tzelepi V, Dimitrakopoulos F, Makatsoris T, Koutras A, Kalofonos H. PO-513 The alternative NF-κB pathway in colorectal cancer. from genetic polymorphisms through mRNA to protein levels. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
11
|
Kottorou A, Sirinian C, Dimitrakopoulos F, Antonacopoulou A, Kalofonos H. PO-112 The role of transcribed ultraconserved regions Uc160 and Uc346 in colorectal cancer progression. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
12
|
Kottorou A, Sirinian C, Dimitrakopoulos F, Antonacopoulou A, Makatsoris T, Kalofonos H. Transcribed ultraconserved regions Uc160 and Uc346 in colon cancer progression. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Dimitrakopoulos FI, Tzelepi V, Kottorou A, Antonacopoulou A, Koutras A, Makatsoris T, Kalofonos H. Clinical significance of the expression of membrane receptors of the alternative nuclear factor-kappaB pathway in non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Kottorou A, Antonacopoulou A, Dimitrakopoulos FI, Diamantopoulou G, Theodorakopoulos T, Oikonomou C, Koukourikou I, Dalla D, Karatasou P, Katsakoulis E, Koutras A, Makatsoris T, Stavropoulos M, Thomopoulos K, Kalofonos H. Diagnostic value of methylation status of T-UCRs for colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Spigel D, Bondarenko I, Losonczy G, Mezger J, Kalofonos H, Reck M, Palmero R, Jang T, Natale R, Sanborn R, Lai J, Kallinteris N, Tang M, Shan J, Gerber D. Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.44] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Maroussi S, Panagopoulos N, Scopa C, Koutras A, Makatsoris T, Dougenis D, Kalofonos H. NF-κB2 genetic variants (rs7897947 and rs12769316) are strongly correlated with the survival of NSCLC patients. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61724-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Marousi S, Koukourikou I, Panagopoulos N, Scopa C, Papadaki H, Dougenis D, Kalofonos H. 226 Genetic variations of NF-κB2 are associated with overall survival of non-small cell lung cancer (NSCLC) patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30113-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Mountzios G, Aravantinos G, Kouvatseas G, Karina M, Samantas E, Papakostas P, Skarlos D, Galani E, Kalofonos H, Makatsoris T, Bafaloukos D, Pectasides D, Fountzilas G. Lessons from the Past: Long-Term Safety and Efficacy Outcomes of a Prematurely Terminated, Randomized Phase III Trial of Precautionary Versus Hemoglobin-Based Erythropoietin Administration for Chemotherapy-Associated Anemia in Patients with Solid Tumors. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Maroussi S, Koukourikou I, Scopa C, Dougenis D, Papadaki H, Kalofonos H. 697: Significance of NF-kB2 genetic variations rs7897947, rs11574852 and rs12769316 in non-small-cell lung cancer: a case–control study. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50615-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Dimitrakopoulos F, Kottorou A, Antonacopoulou A, Scopa C, Dougenis D, Papadaki H, Kalofonos H. 701: The alternative pathway of NF-kB is deregulated in NSCLC? Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50619-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Maroussi S, Koukourikou I, Scopa C, Papadaki H, Kalofonos H. 888 NFkB2 Intron 8 G/T Polymorphism in NSCLC Patients – a New Risk and Prognostic Factor. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71520-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Giannopoulou E, Kotsirilou D, Nikolakopoulos A, Papadimitriou E, Makatsoris T, Kalofonos H. 479 The Impact of EGF on Notch Protein Levels in Non-Small Cell Lung Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71151-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Ifanti AA, Argyriou AA, Kalofonos H. Informal educational interventions for caregivers of adult cancer survivors. J BUON 2012; 17:16-20. [PMID: 22517687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
This review study explores the available data relating to the informal education aspects of effective interventions applied in caregivers of adult cancer survivors to maintain their own health and quality of life (QoL) and as such to provide the optimal care to the cancer patient. The implications of these interventions in oncology practice are also discussed. Available data show that, over the last years, a significant proportion of caregivers of cancer survivors are increasingly offered informal education interventions towards the reduction of their burden. More specifically, educational, skills training, and therapeutic counseling interventions seem to positively affect caregivers' well-being and overall QoL. However, based on available data, one cannot generalize these interventions on improving caregivers' outcomes of daily living activities and QoL. As such, available intervention strategies should be further tested and validated in larger samples, whereas novel health promotion educational approaches are expected to be designed to effectively address and comply with the appropriate needs of caregivers of cancer patients.
Collapse
Affiliation(s)
- A A Ifanti
- Department of Educational Sciences and Early Childhood Education, University of Patras, Rion-Patras, Greece
| | | | | |
Collapse
|
24
|
Kardamakis D, Vomvas D, Iconomou G, Leotsinidis M, Kalofonos H, Assimakopoulos K. Sexual Dysfunction and Depression in Cancer Patients Receiving Radiotherapy: A Prospective Study. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Argyriou AA, Ifanti AA, Kalofonos H. Informal education and health promoting approaches in adult cancer survivors. J BUON 2011; 16:627-634. [PMID: 22331713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
This review looks at the available data relating to the informal education aspects and other health promoting approaches applied by adult cancer survivors to reduce the risk of cancer. The implications of such behavioral interventions on oncology practice are discussed. We also highlight areas of future research to pursue. Available data show that many cancer survivors remain engaged in risky health behaviors post-diagnosis, which are associated with an increased risk of disease's recurrence. However, over the last years patients seem to increasingly receive adequate risk-based medical care. The application of appropriate informal education approaches, such as diet, exercise, and cessation of former unhealthy habits, such as smoking and alcohol has facilitated behavioral changes in cancer survivors, thoroughly improving their well being and overall quality of life (QOL). Most of the research studies published to date have applied structured lifestyle interventions on intensive, individualized counseling sessions delivered by trained personnel or psychosocial-based mediations and reported that these approaches are largely effective in promoting the adoption of a healthier lifestyle in cancer survivors. These interventions have been reported to reduce the risk of cancer recurrence and thus to obtain an obvious positive impact on their well-being and overall QOL. However, there is still insufficient evidence to conclude and support with confidence the effectiveness of any of these behavioral interventions and therefore future interventions should be initiated to assess the long-term effects and validating outcomes of lifestyle and other psychosocial interventions.
Collapse
Affiliation(s)
- A A Argyriou
- Department of Medicine-Division of Oncology, University Hospital of Patras, Rion-Patras, Greece
| | | | | |
Collapse
|
26
|
Dimitrakopoulos F, Antonacopoulou A, Kottorou A, Vlotinou H, Scopa C, Papadaki H, Kalofonos H. 1153 POSTER Uncovering the Unknown Relation Between the Alternative Pathway of NF-kB and NSCLC. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70796-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
27
|
Kalofonos H, Dimitrakopoulos FD, Papadaki H, Antonacopoulou AG, Kottorou AE, Scopa CD, Gotsis A, Mouzaki A. Foxp3 expression in patients with non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Dimitrakopoulos FD, Antonacopoulou AG, Kottorou AE, Vlotinou H, Scopa CD, Papadaki H, Kalofonos H. Shedding light on the alternative pathway of NF-kB in non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Kritikou I, Giannopoulou E, Koutras A, Dimitropoulos K, Kalofonos H. 529 The role of aromatase and epidermal growth factor receptor in non-small cell lung cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71330-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
30
|
Kottorou A, Antonacopoulou A, Tsamandas A, Grivas P, Scopa C, Kalofonos H. 764 Increased expression of NFY-C (Nuclear Factor Y, subunit C) and RORA (Retinoic acid receptor-related Orphan Receptor Alpha) in colorectal adenocarcinoma. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71560-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
31
|
Dimitrakopoulos F, Antonacopoulou A, Maroussi S, Kottorou A, Scopa C, Kalofonos H. 765 An intron 8 polymorphism G/T of NFKB2 gene is associated with NSCLC. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71561-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
32
|
Koutras A, Antonacopoulou A, Fostira F, Briasoulis EC, Sgouros I, Koumarianou A, Xiros N, Christodoulou C, Fountzilas G, Kalofonos H. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3587] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Kalofonos H, Dimitropoulos K, Giannopoulou E, Kyriakopoulou U, Argyriou AA. Lapatinib and sunitinib on glioma cell migration through implication of growth factor with integrins. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Gialeli C, Kletsas D, Mavroudis D, Kalofonos H, Tzanakakis G, Karamanos N. Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies. Curr Med Chem 2009; 16:3797-804. [DOI: 10.2174/092986709789177984] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2009] [Accepted: 07/11/2009] [Indexed: 11/22/2022]
|
35
|
Mountzios G, Dimopoulos M, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou C. 8001 Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Co-operative Oncology Group (HeCOG) study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71523-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
36
|
Mountzios G, Dimopoulos M, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou C. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2009; 20:1362-8. [DOI: 10.1093/annonc/mdn797] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Koutras A, Kritikou I, Giannopoulou E, Dimitropoulos K, Kalofonos H. Dual inhibition of aromatase and epidermal growth factor receptor in non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22189 Background: Recent evidence suggests that estrogen signaling is important in the progression of cancers expressing estrogen receptors (ERs) and may also be involved in the pathogenesis of non-small cell lung cancer (NSCLC). Aromatase is an enzyme complex that catalyses the final step in estrogen synthesis and is present in several tissues, including the lung. In view of a possible functional interaction between the ER and the epidermal growth factor receptor (EGFR) pathways in NSCLC, we investigated the dual inhibition of aromatase and EGFR in NSCLC cell lines. Methods: In the current study we used exemestane, an irreversible steroidal aromatase inactivator, and erlotinib, an EGFR tyrosine kinase inhibitor. The in vitroexperiments were performed using H23 and A549, two NSCLC cell lines with low and high levels of aromatase, respectively. Cell proliferation was measured by MTT assay. Metalloproteinase (MMP) levels were detected by zymography and cell migration was determined by boyden chamber assay. EGFR protein levels detection was performed by immunofluorescense assay. Results: Exemestane and erlotinib inhibited H23 and A549 cell proliferation either alone or in combination, 48 hours after their application. However, the combination of exemestane and erlotinib was more effective than each agent alone, in H23 cells. Furthermore, exemestane decreased MMP-2 and MMP- 9 levels in H23 cells, whereas erlotinib did not. The combination of exemestane and erlotinib had the same effect on MMPs, as exemestane alone. The effect on cell migration was in line with the results in MMPs levels. In A549 cells, no changes in MMPs levels or cell migration were demonstrated. In addition, exemestane altered the location of EGFR protein in H23 cells, but not in A549 cells. Conclusions: Our findings suggest an antiproliferative effect of exemestane and erlotinib in both cell lines, as well as synergy for the combination in H23 cells. The activity of the combination in these cells with low levels of aromatase might involve an additional effect of exemestane on EGFR protein location. Erlotinib did not enhance the effect of exemestane on MMPs secretion and migration in H23 cells. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Koutras
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - I. Kritikou
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - E. Giannopoulou
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - K. Dimitropoulos
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - H. Kalofonos
- Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| |
Collapse
|
38
|
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemother Pharmacol 2007; 62:277-84. [PMID: 17901952 DOI: 10.1007/s00280-007-0604-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2007] [Accepted: 09/10/2007] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas. METHODS This was a multicenter phase-II trial. Protocol treatment consisted of oxaliplatin 80 mg/m(2) followed by irinotecan 160 mg/m(2) administered every 3 weeks. The primary end points were response rate and toxicity, and secondary end points were time to progression and survival. RESULTS Forty-seven patients with liver, bone or multiple visceral metastases entered into the trial and received a median 6 chemotherapy cycles (1-11). The regimen was very well tolerated with one febrile neutropenia case and six cases with diarrhea grade 3 (16%). In intent-to-treat analysis the tumor response rate was 13% (95% CI = 4.8-25.7%) and 12 patients (27%, 95%CI 13.9-40.4%) had at least 4 months' duration of disease stabilization. The median time to progression was 2.7 months and the median survival was 9.5 months, with 40% of patients alive at 1 year. CONCLUSIONS The IROX regimen demonstrated similar efficacy and a favorable toxicity profile compared to other more toxic chemotherapy combinations in patients with poor-prognosis CUP.
Collapse
|
39
|
Antonacopoulou A, Floratou K, Stavropoulos M, Koutras A, Kalofonos H. 3035 POSTER Levels of survivin splice variants correlate to degree of differentiation in colon cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70963-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
40
|
Kaskara AV, Antonacopoulou AG, Scopa CD, Rigopoulos AG, Iconomou G, Georgoulias V, Kalofonos H. Significance of ERCC1 and HER2 expression in human colon carcinomas. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14534 Background: Predictive and prognostic markers need to be established in colon cancer in order to tailor chemotherapy and, therefore, improve efficacy of adjuvant treatment. In this study, expression of the excision repair cross-complementing 1 (ERCC1) and HER2 tyrosine kinase receptor genes was evaluated in human colon carcinomas. Moreover, expression levels were associated with survival, time to disease progression and various clinicopathologic parameters. Methods: Fifty formalin fixed paraffin embedded tissues of primary colon carcinomas, resected from an equal number of patients at the University Hospital of Patras, Greece were studied. Forty four patients were treated with adjuvant chemotherapy and four patients with chemotherapy for advanced disease. Total RNA was extracted from tissues, quantified and reverse transcribed. Levels of ERCC1 and HER2 mRNA were quantified using Taqman probes in real time PCR and expressed relative to a calibrator. Results: ERCC1 and HER2 mRNA were detected in 92% and 82% of cases respectively, although overexpression was observed in 43.5% and 26.8%. Levels of expression were not related to age, stage, grade and overall survival. There was a significant association between overexpression of ERCC1 and time to disease progression (p<0.05) although this was not observed for HER2. There was a trend towards decreased relapse following adjuvant therapy in patients with low expression levels of ERCC1 and HER2 mRNA levels. However this difference failed to reach significance. Expression levels of ERCC1 and HER2 were not correlated with each other. Furthermore, coexpression of the two molecules was not related to time to disease progression. Additionally, 99.5% and 93.7% of patients with low expression of ERCC1 and HER2, respectively, having received adjuvant therapy were alive at the 36 months follow up. Conclusions: These data suggest that overexpression of ERCC1 is significantly associated with time to disease progression in colon cancer. Further studies of ERCC1 as a prognostic or predictive marker are warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. V. Kaskara
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - A. G. Antonacopoulou
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - C. D. Scopa
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - A. G. Rigopoulos
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - G. Iconomou
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - V. Georgoulias
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| | - H. Kalofonos
- University of Patras, Patra, Greece; University of Crete, Heraklion, Crete, Greece
| |
Collapse
|
41
|
Gerolymos M, Koutras A, Kontogeorgou E, Iconomou G, Vourli G, Tsiata E, Makatsoris T, Chrysanthopoulos C, Kalofonos H. Phase II study of irinotecan plus leucovorin and bolus 5 fluorouracil as first or second line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15128 Background: The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU) / leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma. Methods: Treatment consisted of irinotecan 80 mg/m2 intravenously (i.v.), followed by LV 200 mg/m2 (i.v.) and 5- FU 450 mg/m2 as an i.v. bolus. Treatment was administered weekly for 6 weeks, followed by a 2-week rest period. Results: Thirty-one patients (23 chemo-naïve, 8 chemo-exposed) were enrolled. The overall response rate was 22.6% and the disease control rate was 38.7%. Among the patients who received the regimen as first-line treatment, objective response rate was 30.4% and the disease control rate was 52.1%. However, progression of the disease was recorded in all the patients receiving the combination as second-line chemotherapy. The median time to disease progression (TTP) was 4 months and the median duration of survival was 7 months. The median TTP was 6 months for patients treated with first-line chemotherapy and 2.5 for those who received study treatment as second line. Furthermore, the median survival duration was 8 months and 6 months, respectively. The most frequent grade 4 toxicity was febrile neutropenia. Grade 3 or 4 non-hematological toxicities were rare. There were no treatment-related deaths. Conclusions: The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated, with efficacy comparable to that of other regimens in advanced gastric cancer. Accordingly, this regimen can be regarded as one of first-line options, particularly in patients who can not tolerate aggressive chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Gerolymos
- University Hospital of Patras, Rio Patras, Greece
| | - A. Koutras
- University Hospital of Patras, Rio Patras, Greece
| | | | - G. Iconomou
- University Hospital of Patras, Rio Patras, Greece
| | - G. Vourli
- University Hospital of Patras, Rio Patras, Greece
| | - E. Tsiata
- University Hospital of Patras, Rio Patras, Greece
| | | | | | - H. Kalofonos
- University Hospital of Patras, Rio Patras, Greece
| |
Collapse
|
42
|
Antonacopoulou A, Tsamandas A, Skopa C, Bonikos D, Kalofonos H. Potential role of ERBB-2 and cyclooxygenase-2 expression in human colon carcinomas. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3608 Background: ERBB2 receptor tyrosine kinase and cyclooxygenase-2 (COX-2) represent promising molecular targets for cancer therapy and/or prevention. This study investigates the relation between ERBB2 and COX-2 expression in human colon carcinomas. Methods: Immunohistochemistry to detect membranous ERBB2 and cytoplasmic COX-2 expression was performed on 124 archived human primary colon carcinomas and matched normal tissues. Results were expressed as % positive cells. In addition, the mRNA levels of ERBB2 and COX-2 were evaluated in a subset of the colonic tissue samples (46 tumor, 7 normal) using real time RT-PCR (expression relative to a calibrator) Results: The results are displayed in the table . ERBB2 and COX-2 expression was higher in well-differentiated tumors (p<0.001 and p<0.05, respectively). However, both ERBB2 and COX-2 protein levels increased in a statistically significant way towards more advanced stages. Linear regression revealed a strong positive correlation between ERBB2 and COX-2 expression in neoplastic populations (r=0.83, p=0.000082 for protein; r=0.411, p=0.00404 for mRNA). Thus, ERBB2 and COX-2 may transcriptionally regulate each other in colon carcinomas. Conclusions: Overexpression of ERBB2 and COX-2 may represent an early dysfunctional event in human colon carcinogenesis regarding tumor differentiation. However, their expression is increased in advanced stages. These markers may constitute important targets for chemoprevention or adjunct therapy of well-differentiated colon carcinomas. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Antonacopoulou
- University of Patras Clinical Oncology Laboratory, Patras, Greece; University of Patras, Patras, Greece
| | - A. Tsamandas
- University of Patras Clinical Oncology Laboratory, Patras, Greece; University of Patras, Patras, Greece
| | - C. Skopa
- University of Patras Clinical Oncology Laboratory, Patras, Greece; University of Patras, Patras, Greece
| | - D. Bonikos
- University of Patras Clinical Oncology Laboratory, Patras, Greece; University of Patras, Patras, Greece
| | - H. Kalofonos
- University of Patras Clinical Oncology Laboratory, Patras, Greece; University of Patras, Patras, Greece
| |
Collapse
|
43
|
Giannopoulou E, Ravazoula P, Kalofonos H, Makatsoris T, Kardamakis D. Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo 2006; 20:421-5. [PMID: 16724682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
BACKGROUND Hypoxia-inducible-factor-1 (HIF-1) is present at high levels in human tumors and plays a crucial role in tumor promotion by up-regulating several target genes. HIF-1 stimulates the production of NO through the induction of inducible NO synthase (iNOS). PATIENTS AND METHODS Sixty-three human astrocytic gliomas were analyzed by immunohistochemistry for HIF-1alpha and iNOS using formalin-fixed paraffin-embedded material. In 39 cases, the results of immunohistochemistry were correlated with the clinical outcomes. RESULTS HIF-1alpha was detected only in astrocytic gliomas grades III and IV, both in the nucleus and in the cytoplasm. The iNOS expression was increased in astrocytic gliomas grades I, II and III and was statistically significantly decreased in astrocytic gliomas grade IV. iNOS was localized round the capillary vessels as well. Statistical analysis showed that the HIF-1alpha and iNOS expressions did not correlate with patient survival. CONCLUSION We believe that HIF-1alpha and iNOS expressions merit further investigations in order to understand the biology of astrocytic gliomas. More data are needed from prospective studies.
Collapse
Affiliation(s)
- E Giannopoulou
- Laboratory of Clinical Oncology, University of Patras Medical School, 26500, Rion, Greece
| | | | | | | | | |
Collapse
|
44
|
Likaki-Karatza E, Ravazoula P, Androutsopoulos G, Michail G, Batistatou A, Tzorakoleftherakis E, Kalofonos H, Kourounis G. Correlation of mammographic appearance and molecular prognostic factors in high-grade breast carcinomas. EUR J GYNAECOL ONCOL 2006; 27:39-41. [PMID: 16550966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The aim of our study was to evaluate the association between the mammographic appearance and the biologic characteristics of high-grade breast carcinomas. Three hundred and twenty patients with breast carcinomas were studied. Histological examination showed 83 (26%) high-grade ductal carcinomas. Immunohistochemistry was carried out by using antibodies against estrogen receptor (ER), progesterone receptor (PR), HER-2/neu, p53 and cathepsin D. In 60/83 high-grade carcinomas we studied the mammographic appearance. Asymmetric density with poorly defined margins without microcalcifications was the major mammographic finding in 49/60 (approximately 82%) high-grade ductal carcinomas. HER-2/neu positivity (68.7%) and p53 positivity (48.2%) were statistically correlated with asymmetric density with poorly defined margins without microcalcifications in high-grade carcinomas. We observed loss of ER and PR receptors in 50%, whereas loss of PR receptors was observed in 65% of high-grade breast carcinomas. Cathepsin D (> 20%) was detected in 38.5% of high-grade carcinomas. Our findings suggest a significant relationship between mammographic appearance and biologic markers in high-grade breast carcinomas.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor/analysis
- Biopsy, Needle
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Intraductal, Noninfiltrating/genetics
- Carcinoma, Intraductal, Noninfiltrating/metabolism
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Cathepsin D/metabolism
- Cohort Studies
- Female
- Gene Expression Regulation, Neoplastic
- Genes, p53
- Humans
- Immunohistochemistry
- Mammography
- Middle Aged
- Molecular Biology
- Neoplasm Staging
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/analysis
- Sensitivity and Specificity
Collapse
|
45
|
Briasoulis E, Samantas E, Kalofonos H, Skarlos D, Makatsoris T, Christodoulou C, Fountzilas G, Bamias A, Dimopoulos MA, Kosmidis P, Pavlidis N. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Cancer Chemother Pharmacol 2005; 56:521-8. [PMID: 15959778 DOI: 10.1007/s00280-004-0994-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2004] [Accepted: 11/25/2004] [Indexed: 10/25/2022]
Abstract
AIM The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. METHODS Successive cohorts of AS-SCLC patients were treated with irinotecan administered as a single 1-h infusion in combination with fixed doses of cisplatin (20 mg/m(2)) and etoposide (75 mg/m(2)), both given for three consecutive days (ECI regimen). Irinotecan dose was escalated from 60 mg/m(2) by 40-mg/m(2) increments. At mid-step between the maximum tolerated dose (MTD) and the previous dose level, patients were randomized for the day of administration of irinotecan (day 1 vs day 3). RESULTS A total of 36 AS-SCLC patients received 166 courses of treatment at four dose levels. The MTD of irinotecan was 140 mg/m(2) (three dose-limiting toxicities, DLTs), and the recommended optimal dose (ROD) 120 mg/m(2) (two DLTs). DLTs were febrile neutropenia and grade 3 diarrhea. Other toxicities were mild. No difference in toxicity was seen between the two time schedules. A 77% (95% CI 63.25-90.75%) response rate was recorded among 31 evaluable patients and the median survival was 12 months. CONCLUSIONS The ECI regimen was well tolerated and showed considerable activity in patients with AS-SCLC. Phase II/III evaluation is ongoing.
Collapse
Affiliation(s)
- E Briasoulis
- Medical Oncology Department, University Hospital, Ioannina, Greece.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Nikolaou M, Valavanis C, Lekka I, Aravantinos G, Fountzilas G, Skarlos D, Kalofonos H, Kostopoulou V, Arapantoni Dadioti P, Pectasides D. Molecular markers in extragonadal germ cell tumors (EGCTs): A matched-case control study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Nikolaou
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - C. Valavanis
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - I. Lekka
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - G. Aravantinos
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - G. Fountzilas
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - D. Skarlos
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - H. Kalofonos
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - V. Kostopoulou
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - P. Arapantoni Dadioti
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| | - D. Pectasides
- Attikon Univ Hosp, Athens, Greece; Metaxas Memorial Cancer Hosp, Piraeus, Greece; Ag. Anargiri Cancer Hosp, Athens, Greece; Papageorgiou Hosp, Thessaloniki, Greece; Henry Dunant Hosp, Athens, Greece; Univ Hosp of Patras, Patras, Greece
| |
Collapse
|
47
|
Xiros N, Papacostas P, Economopoulos T, Samelis G, Efstathiou E, Kastritis E, Kalofonos H, Onyenadum A, Skarlos D, Bamias A, Gogas H, Bafaloukos D, Samantas E, Kosmidis P. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16:773-9. [PMID: 15802284 DOI: 10.1093/annonc/mdi160] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients with advanced pancreatic cancer. PATIENTS AND METHODS Patients with previously untreated, locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8 and carboplatin at an AUC of 4 on day 8 of a 3-week cycle, for a total of six cycles. Primary end points were response rate and clinical benefit; secondary end points were, survival, time to progression (TTP) and toxicity. RESULTS A total of 50 patients were enrolled in the study, 47 of whom were eligible for treatment. The median age was 63 years (range 34-76) and the median Karnofsky performance status (PS) was 80%. Patients received a median of six cycles (range 1-11). Among 35 patients evaluable for response, eight (17%) achieved partial response; 15 (32%) and 12 (25%) patients had stable and progressive disease, respectively. The median overall survival was 7.4 months; the median TTP was 4.4 months and the 1-year survival was 28%. The observed clinical benefit response was remarkable. After the second cycle of chemotherapy, 21 of 31 (68%) patients experienced pain improvement and reduced analgesic consumption. At the same time, 35% and 56% of our patients significantly improved their Karnofsky PS and weight, respectively. Overall, the treatment was well tolerated. The most common grade 3-4 toxicities were hematological, including 8% anemia, 6% neutropenia and 13% thrombocytopenia. CONCLUSIONS The combination of gemcitabine plus carboplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer. This regimen has an acceptable toxicity profile and provides a significant clinical benefit, and hence warrants further investigation.
Collapse
Affiliation(s)
- N Xiros
- Second Department of Internal Medicine, Propaedeutic and Research Institute, University General Hospital 'Attikon', University of Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16:950-7. [PMID: 15829494 DOI: 10.1093/annonc/mdi190] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
PURPOSE Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0.6 position of guanine. The methyl adducts are removed by the DNA repair enzyme AGAT. As demonstrated by in vitro studies, cisplatin (CDDP) is able to down-regulate the AGAT activity, suggesting that CDDP could enhance the antitumor activity of TMZ. We designed a randomized phase II study to evaluate and compare the activity and safety profile of the combination versus single-agent TMZ in patients with advanced melanoma. PATIENTS AND METHODS From January 2000 to April 2002, 132 patients were enrolled on the study. Patient and tumor characteristics were well balanced between the two arms. Patients with cerebral metastases were included. Patients received TMZ 200 mg/m(2)/day orally for five consecutive days every 4 weeks or TMZ + CDDP 200 mg/m(2) daily on days 1-5 and 75 mg/m(2) of CDDP on day 1. RESULTS Tumor responses (complete and partial responses) were seen in 16 patients (26%) in arm A and 19 patients (29%) in arm B. The median time to progression (TTP) was 3.8 months in arm A and 5.8 months in arm B. The median overall survival (OS) was 11.5 months in arm A and 12 months in arm B. The difference between treatment arms regarding objective response rates, TTP and OS were not statistically significant. Toxicity was comparable between the two arms for anemia, leukopenia, neutropenia, thrombocytopenia, fatigue, constipation and arthralgias/myalgias. There was significantly more grade 3 and 4 emesis in the combination arm. CONCLUSIONS No clear benefit in terms of response rates, median TTP or OS was shown with the combination of TMZ + CDDP. Additionally, the combination was associated with higher incidence of grade 3 and 4 emesis.
Collapse
Affiliation(s)
- D Bafaloukos
- Department of Oncology, Metropolitan Hospital, Faliro, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Briasoulis E, Samantas E, Kalofonos H, Skarlos D, Christodoulou C, Fountzilas G, Barnias A, Dimopoulos M, Kosmidis P, Pavlidis N. 807 Phase I trial of cisplatin, etoposide and CPT-11 triplet in patients with advanced stage SCLC. A hellenic cooperative oncology group study. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90832-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
50
|
Abstract
Three potential applications of NO-donating NSAIDs in human cancer include their use: as chemopreventive agents; against already developed cancers (chemotherapy); and for the control of cancer symptoms, notably cancer pain. The evidence to date of greater safety and enhanced efficacy of NO-donating NSAIDs underscores their potential to prevent colon cancer and overcome the limitations of traditional NSAIDs. NO-donating NSAIDs affect several pathways critical to colon carcinogenesis and this may explain in part their greater efficacy in colon cancer prevention as assessed in preclinical models.
Collapse
Affiliation(s)
- B Rigas
- American Health Foundation, 1 Dana Road, Valhalla, NY 10595, USA.
| | | | | | | |
Collapse
|